Literature DB >> 11172945

Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

A Inoue1, H Kunitoh, I Sekine, M Sumi, K Tokuuye, N Saijo.   

Abstract

PURPOSE: To retrospectively evaluate the risk factors for acute radiation pneumonitis (RP) and long-term prognosis of patients with lung cancer treated by thoracic radiotherapy. METHODS AND MATERIALS: Of the 256 lung cancer patients who underwent definitive thoracic radiotherapy between June 1988 and May 1998, the 191 patients who were capable of being evaluated were divided into three groups according to the grade of RP. RP was defined as "severe," when it caused severe clinical symptoms, such as intractable cough, dyspnea at rest, and the need for oxygen or steroid therapy. The definition was made by using a modification of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer acute radiation morbidity scoring criteria. Factors that influenced the incidence of severe RP were assessed by using the Mantel-Haenszel chi(2) test in the univariate analysis and the logistic regression test in the multivariate analysis. Survival rates was calculated by using the Kaplan-Meier method, and the p values indicating the significance of differences between the RP groups were calculated by the log-rank test.
RESULTS: Of the 94 patients (49%) who experienced clinical RP in this study, the RP was mild in 69 (36%) and severe in 25 (13%) patients. The 3-year survival rates of the patients who experienced no, mild, and severe RP were 33.4%, 38.2%, and and 0%, respectively, and the survival rate of the patients who experienced severe RP was significantly poorer than the other two groups combined (p = 0.0028). The incidence of severe RP did not correlate with any of the baseline patient characteristics, radiotherapeutic factors, or chemotherapeutic variables. Two clinical risk factors were identified from medical records before radiotherapy: low PaO2 (< 80 torr) and high C-reactive protein (CRP) (> 1.0 ng/mL). Both of them were significantly related to the development of severe RP in the univariate analysis (p = 0.004 and 0.013, respectively), and low PaO2 remained a significant risk factor in the multivariate analysis (p = 0.034). Multivariate analysis also revealed the occurrence of severe RP to be the most important factor determining poor survival (p = 0.0065). There was no significant difference in survival rate according to whether the patients had been treated with corticosteroids.
CONCLUSION: Mild and severe RP occurred in 69 (36%) and 25 (13%), respectively, of 191 lung cancer patients who had undergone irradiation of the chest. Only severe RP was an adverse prognostic factor. Low PaO2 (< 80 torr) before radiotherapy was a significant risk factor predictive of severe RP. The role of corticosteroids in RP could not be accurately determined.

Entities:  

Mesh:

Year:  2001        PMID: 11172945     DOI: 10.1016/s0360-3016(00)00783-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  47 in total

1.  The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response.

Authors:  Jingfang Mao; Zafer Kocak; Sumin Zhou; Jennifer Garst; Elizabeth S Evans; Junan Zhang; Nicole A Larrier; Donna R Hollis; Rodney J Folz; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-02       Impact factor: 7.038

2.  Incorporation of pre-therapy 18 F-FDG uptake data with CT texture features into a radiomics model for radiation pneumonitis diagnosis.

Authors:  Gregory J Anthony; Alexandra Cunliffe; Richard Castillo; Ngoc Pham; Thomas Guerrero; Samuel G Armato; Hania A Al-Hallaq
Journal:  Med Phys       Date:  2017-05-22       Impact factor: 4.071

Review 3.  Prediction of radiation pneumonitis in lung cancer patients: a systematic review.

Authors:  Xiao-Jing Zhang; Jian-Guo Sun; Jie Sun; Hua Ming; Xin-Xin Wang; Lei Wu; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-29       Impact factor: 4.553

4.  Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer.

Authors:  Sun Kim; In-Jae Oh; Seo-Yeon Park; Jang-Hyeon Song; Hyun-Ju Seon; Yun-Hyeon Kim; Seong-Hoon Yoon; Jin-Yeong Yu; Bo-Ram Lee; Kyu-Sik Kim; Young-Chul Kim
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

Review 5.  Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction?

Authors:  Jacqueline P Williams; Carl J Johnston; Jacob N Finkelstein
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

Review 6.  Molecular mechanisms and treatment of radiation-induced lung fibrosis.

Authors:  Nian-Hua Ding; Jian Jian Li; Lun-Quan Sun
Journal:  Curr Drug Targets       Date:  2013-10       Impact factor: 3.465

7.  Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer.

Authors:  Cem H Misirlioglu; Taciser Demirkasimoglu; Bulent Kucukplakci; Ergun Sanri; Kadri Altundag
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

8.  Validation and optimization of a predictive model for radiation pneumonitis in patients with lung cancer.

Authors:  Charlott Mörth; Ioannis Kafantaris; Markus Castegren; Antonios Valachis
Journal:  Oncol Lett       Date:  2016-06-06       Impact factor: 2.967

Review 9.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22

10.  Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer.

Authors:  M Moreno; J Aristu; L I Ramos; L Arbea; J M López-Picazo; M Cambeiro; R Martínez-Monge
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.